A. Kafantari

Community dysfunction in schizophrenia: Rate-limiting factors

M. Kosmidis, P. Petrikis, V. Bozikas, 2006, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia

I. Niopas, V. Bozikas, A. Karavatos, 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

Performance of Greek Demented and Nondemented Subjects on the Greek Version of the Mattis Dementia Rating Scale. A Validation Study

Z. Katsarou, S. Bostantjopoulou, V. Tsipropoulou, 2010, The International journal of neuroscience.

Impact of cognitive dysfunction and symptoms on social outcome of outpatients with schizophrenia

M. Kosmidis, P. Petrikis, V. Bozikas, 2003 .

Verbs with alternating transitivity in Parkinson’s disease: Evidence from production and comprehension tasks

S. Stavrakaki, E. Anagnostopoulou, A. Alexiadou, 2003, Brain and Language.

Assessing quality of life in Parkinson's disease: Can a short‐form questionnaire be useful?

V. Peto, Z. Katsarou, S. Bostantjopoulou, 2004, Movement disorders : official journal of the Movement Disorder Society.

No increased levels of the nicotine metabolite cotinine in smokers with schizophrenia

I. Niopas, V. Bozikas, A. Karavatos, 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.